A Prospective Study on Incidence of Sexual Dysfunctions in Patients Newly Prescribed Ssris

Abstract

Introduction: Depression is a prevalent mental health disorder, with selective serotonin reuptake inhibitors (SSRIs) being the first line treatment for pharmacological management. Despite their effectiveness, SSRIs are frequently associated with sexual dysfunctions in multiple domains. Such side effects can impact treatment adherence and overall prognosis.

Objective: This study investigates the incidence, onset, and types of sexual dysfunction in patients newly prescribed SSRIs for depression.

Methodology: This longitudinal, analytical study included 119 drug-naïve patients aged 18–50 years, diagnosed with depression and prescribed SSRI monotherapy. Participants were assessed using the Hamilton Depression Rating Scale (HAM-D) and the Changes in Sexual Functioning Questionnaire (CSFQ-14) at baseline, and at 2, 4, and 12 weeks. Patients with pre-existing sexual dysfunctions or other medical conditions affecting sexual health were excluded. Statistical analysis was performed using SPSS v28.0, with T-tests and chi-square tests employed for comparisons.

Results and Discussion: Out of 119 participants, data from 100 patients were analysed due to follow-up losses. Sexual dysfunction was observed in 41% of patients after 12 weeks, affecting all domains but mainly affecting excitement, orgasm, and interest. No statistically significant differences were found in the incidence of dysfunction across gender or socio-demographic variables, although the highest prevalence was noted in the 25–35 age group. These findings align with global reports on SSRI-associated sexual dysfunction.

Conclusion: The study highlights the high incidence rate for onset of sexual dysfunctions and underscores the necessity for clinicians to regularly assess and address potential sexual side effects with patients to enhance treatment adherence.